Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Receivables (2020 - 2023)

Immuneering (IMRX) has 4 years of Change in Receivables data on record, last reported at -$1046.0 in Q2 2023.

  • For Q2 2023, Change in Receivables rose 98.97% year-over-year to -$1046.0; the TTM value through Mar 2024 reached -$1046.0, up 99.62%, while the annual FY2023 figure was -$12417.0, 94.69% up from the prior year.
  • Change in Receivables reached -$1046.0 in Q2 2023 per IMRX's latest filing, up from -$11371.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $278185.0 in Q3 2020 and bottomed at -$250978.0 in Q4 2021.
  • Average Change in Receivables over 4 years is -$27133.6, with a median of -$17550.5 recorded in 2021.
  • The widest YoY moves for Change in Receivables: up 535.73% in 2022, down 3847.7% in 2022.
  • A 4-year view of Change in Receivables shows it stood at -$78035.0 in 2020, then crashed by 221.62% to -$250978.0 in 2021, then surged by 76.98% to -$57763.0 in 2022, then soared by 98.19% to -$1046.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$1046.0 in Q2 2023, -$11371.0 in Q1 2023, and -$57763.0 in Q4 2022.